RESULTS: A total of 181 patients met inclusion criteria, of which 124 and 57 patients were on dabigatran and rivaroxaban, respectively. Those with renal impairment taking dabigatran were older, with an average age of 69 years compared to 65 years without (p=0.03). No difference in other clinical characteristics was noted. The highest (p=0.012) and average (p=0.021) ACTs were higher in patients with renal impairment on dabigatran compared to those without. In patients with renal impairment, higher averaged ACT values were seen in the dabigatran cohort compared to the rivaroxaban cohort (p=0.004). No difference in bleeding complications at 48 hours and 2 weeks was noted among all cohorts.